Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumab
Background
Atypical tumor response patterns associated with immunotherapies pose significant challenges for assessing treatment response and clinical decision-making. We characterized the epidemiology, clinical impact, and molecular determinants of ps…